HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials

Alessandra Gennari, Maria Pia Sormani, Paolo Pronzato, Matteo Puntoni, Mariantonietta Colozza, Ulrich Pfeffer, Paolo Bruzzi

Research output: Contribution to journalArticle

Abstract

Background: Adjuvant chemotherapy with anthracyclines improves disease-free and overall survival compared with non-anthracycline-based adjuvant chemotherapy regimens in the treatment of early breast cancer. The role of HER2 status as a marker of anthracycline responsiveness has been explored by subset analyses within randomized clinical trials, with inconsistent results. We performed a pooled analysis of the interaction between HER2 status and the efficacy of adjuvant anthracyclines based on the published subset data. Methods: We searched literature databases to identify randomized trials that compared anthracycline-based with non-anthracycline-based adjuvant chemotherapy regimens in the treatment of early breast cancer and reported efficacy data according to HER2 status. Log hazard ratios (HRs) for disease-free and overall survival were pooled across the studies according to HER2 status by inverse variance weighting. A pooled test for treatment by HER2 status interaction was performed by weighted linear meta-regression. All statistical tests were two-sided. Results: Eight studies (with 6564 randomly assigned patients, of whom 5354 had HER2 status information available) were eligible for this analysis. In HER2-positive disease (n = 1536 patients), anthracyclines were superior to non-anthracycline-based regimens in terms of disease-free (pooled HR of relapse = 0.71; 95% confidence interval [CI] = 0.61 to 0.83; P

Original languageEnglish
Pages (from-to)14-20
Number of pages7
JournalJournal of the National Cancer Institute
Volume100
Issue number1
DOIs
Publication statusPublished - Jan 2008

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials'. Together they form a unique fingerprint.

  • Cite this